On-site tests must accurately identify cannabis exposure because this drug accounts for the highest prevalence in workplace drug testing and driving under the influence of drugs (DUID) programs.METHODS:Ten cannabis smokers (9 males, 1 female) provided written informed consent to participate in this...
Small sex differences in therapeutic drug potency are unlikely to be important clinically, because drug dose can be readily adjusted up or down to compensate for any individual difference in drug effect. In contrast, large sex differences in therapeutic drug potency, or sex differ- ences in ...
. Few cannabinoids have been compared in femalesvsmales using models of persistent pain, which are likely to be more predictive of cannabinoid analgesic potential in humans. In the complete Freund’s adjuvant (CFA) model of paw inflammatory pain, systemically administered THC produced greater anti-a...
In late 2008, several synthetic cannabinoids were detected in herbal smoking mixtures. Typical of these products were 'Spice Gold', 'Spice Silver' and 'Yuc... S Hudson,J Ramsey - 《Drug Testing & Analysis》 被引量: 243发表: 2011年 ...
To draw the right conclusions regarding new intake of these substances in situations of repeated urinary drug testing, knowledge of their elimination rate in urine is essential. We report data from consecutive urine specimens from five subjects after ingestion of synthetic cannabinoids. Urinary ...
Other cannabinoids such as CBC and CBN were also quantifiable, but Δ8-THC was not detected in any sample. However, other authors have reportedly identified inflorescence samples with Δ8-THC concentrations up to 4.9 mg/g [44], well above the LoQ of the present method. Accordingly, the ...
Nadine Roth & Volker Auwärter Hair analysis for cannabinoids is extensively applied in workplace drug testing and in child protection cases, although valid data on incorporation of the main analytical targets, ∆9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-THC (THC-COOH), into human...
Nabiximols, also known as Sativex®, is a Food and Drug Administration (FDA)- approved oromucosal spray containing CBD and THC extracts in a 1:1 ratio derived from the cannabis plant that is approved for treatment of spasticity associated with multiple sclerosis. Epidiolex® is pharmaceutical...
present investigators it was not possible to include these covariates in the present analysis. The USA formed a suitable setting for this epidemiological investigation as the required data on TCR and other drug and cannabis use by State and different ethnicities over time is readily publicly ...
The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the t